

HVD Life Science and Poietis announce a distribution partnership for Poietis' Next-Gen Bioprinting platform, NGB-R™, across the territories of AUSTRIA and GERMANY

March 28th, 2024 – Pessac, France and Vienna, Austria

Poietis and HVD Life Sciences are pleased to announce the signature of their collaboration for the distribution of Poietis' Next-Generation Bioprinting (NGB) platform designed for translational research in Austria and Germany.

Based on an exclusive laser-assisted bioprinting technology combined with more conventional bioextrusion, Poietis' multimodal robotic bioprinting platform NGB-R™ empowers R&D in cell biology, allows to easily create complex 3D tissue models and accelerate the transition to clinical applications.

Werner Buergler, Sales Director of HVD Life Science Vertriebs GmbH, expressed his enthusiasm about the partnership, stating: *"We are excited to collaborate with POIETIS, a company renowned for its groundbreaking work in bioprinting. The distribution of the NGB-R™ Bioprinter in Austria and Germany is a testament to our dedication to bringing cutting-edge technology and solutions to the scientific community. This partnership not only enhances our product portfolio but also empowers researchers with the tools they need to advance their work in creating sustainable and life-saving solutions."*

The collaboration between HVD Life Science and POIETIS is set to transform the landscape of biomedical research and development in Austria and Germany. By providing access to the NGB-R™ Bioprinter, the partnership aims to accelerate advancements in tissue engineering, drug discovery, and regenerative medicine, ultimately contributing to the betterment of human health. The NGB-R™ Bioprinter represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI- assisted software etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.

Bruno Brisson, Poietis' Co-Founder and Chief Business Officer comments: *"We are delighted to start the collaboration with HVD Life Science, an established and reputable company with the expertise and experience to deliver high-end life-sciences instruments and technologies into the market. Austria and Germany are key territories in Europe for biotechnologies, research in biology and healthcare in general. This new distribution agreement is part of our strategy to promote NGB-R™ through high-quality partners selected for their network and understanding of our customers' needs"*.

About the companies:

HVD Life Sciences

HVD Life Sciences is a marketing and distribution company that specializes in sourcing, supplying and supporting life science solutions. We bring a global perspective to our business worldwide, covering regions including Central and Southeast Europe, the Middle East, Africa, the Commonwealth of Independent States, and the Far East. We offer a wide range of high quality products from carefully selected manufacturers of innovative and industry-leading tools and technologies. With all of our suppliers, we focus on building strong relationships that will ensure long-term success for our customers, our partners and ourselves.



<https://hvdlifesciences.com/about-us.html>

Poietis

Poietis is a health technology company specialized in the development and manufacturing of human tissues by bioprinting. Its main mission is to develop new therapeutic solutions based on its expertise in bioprinting technologies and in particular in high resolution laser bioprinting. Poietis has developed the Next Generation Bioprinting (NGB) platform, which is available in a research version for tissue bioengineering (NGB-R™) and a clinical grade version (NGB-C™) compatible with Good Manufacturing Practices for ATMPs and implantable bioprinted tissue production. This multimodal, robotic platform allows the fabrication of complex tissues while ensuring repeatability and reproducibility. Poietis' bioprinting technology is the result of innovative research conducted for over ten years at Inserm and the University of Bordeaux. Founded in September 2014, Poietis operates a portfolio of over 100 patents and currently employs 22 people.

For more information on the NGB-R bioprinting platform, please reach out to: ngb-platform@poietis.com

www.poietis.com

